Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Sponsor
Henan Cancer Hospital
Study ID
NCT03986515
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Cancer
  • Apatinib
  • Mucosal Melanoma
  • SHR-1210

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

There is still no effective treatment for advanced mucosal melanoma at present. The efficacy of single-agent PD-1 inhibitors is less than 20%. It is urgent to explore regimens to improve the efficacy of PD-1 inhibitors in patients with advanced mucosal melanoma. This study is performed to explore the safety and efficacy of apatinib plus SHR-1210 in patients with advanced mucosa melanoma whose diseases progress after chemotherapy.

Key Dates

Start date
Jun 4, 2019
Status verified
Jun 2019
Primary completion
May 31, 2021
Completion
May 31, 2022

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events. SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events. (the first dose of SHR-1210 is set on the 3-5 days after apatinib

Primary Outcome Measure

objective response rate [ Time Frame: three months ]

Central Contacts

Related Studies